HALEY BOMAL: Open Payments
NPI 1376302315 · LITTLETON, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 53 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $773 · 2025 $893
Food & beverage: $893
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $221 |
| Alkermes, Inc. | 10 | $151 |
| Otsuka America Pharmaceutical, Inc. | 5 | $83 |
| Braeburn Inc. | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Lundbeck LLC | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $32 |
Products named: VRAYLAR, ARISTADA, REXULTI, BRIXADI, TRINTELLIX, CAPLYTA, UZEDY, HETLIOZ.
Industry payments across CO — which companies pay providers there.
